WuXi Biologics, Recro Gainesville Expand

By Akia Thorpe -

November 9, 2018

A roundup of the latest news from suppliers, contract development and manufacturing organizations and contract manufacturing organizations, featuring WuXi Biologics and Recro Gainesville.

Biologics Manufacturing 

WuXi Biologics Begins Construction of Biologics Manufacturing Center in China
WuXi Biologics, part of WuXi AppTec, a Shanghai, China-headquartered contract service provider, has begun construction on a biologics manufacturing center of excellence, in Shijiazhuang, China.

The new biologics center with 48,000-liter bioreactor capacity will use disposable bioreactors and be built to meet cGMP standards of the US, the European Union, and China. It will be the eighth drug-substance manufacturing facility of WuXi Biologics, which expects to have more than 220,000 liters of manufacturing capacity by 2021.

Source: WuXi Biologics

 

Formulation/Drug Product Manufacturing

Recro Gainesville Adds New Facility in Georgia
Recro Gainesville, a contract development and manufacturing organization (CDMO) of solid oral dose products and a wholly owned subsidiary of the specialty pharmaceutical company, Recro Pharma, has added a 24,000-square-foot facility, which includes high-potent material processing space, near its existing 97,000-square-foot contract pharmaceutical development and manufacturing plant.

The company says the expanded capabilities will allow it to provide clients with a broader range of CDMO services, from benchtop through commercialization. Clients can obtain manufacturing services ranging from formulation and development through clinical trial material production for Phase I and beyond.

Source: Recro Gainesville